M. A. Hussein

1.4k total citations
26 papers, 380 citations indexed

About

M. A. Hussein is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, M. A. Hussein has authored 26 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 12 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in M. A. Hussein's work include Multiple Myeloma Research and Treatments (14 papers), Cancer Treatment and Pharmacology (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). M. A. Hussein is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Cancer Treatment and Pharmacology (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). M. A. Hussein collaborates with scholars based in United States, Switzerland and Greece. M. A. Hussein's co-authors include James R. Berenson, Rubén Niesvizky, Nikhil C. Munshi, Jonathan G. Drachman, Nancy Whiting, Ronald Sobecks, Meletios Α. Dimopoulos, Arlene S. Swern, Rachid Baz and K. Mullen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

M. A. Hussein

24 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. A. Hussein United States 10 198 159 119 116 48 26 380
Anup J. Devasia India 11 254 1.3× 92 0.6× 115 1.0× 54 0.5× 37 0.8× 79 392
A. Zuiable United Kingdom 8 310 1.6× 121 0.8× 94 0.8× 38 0.3× 28 0.6× 13 348
Arif Alam United Arab Emirates 9 126 0.6× 133 0.8× 39 0.3× 70 0.6× 19 0.4× 26 333
Waleed Sabry Canada 10 143 0.7× 98 0.6× 93 0.8× 33 0.3× 16 0.3× 23 266
Ozan Salim Türkiye 11 84 0.4× 52 0.3× 44 0.4× 49 0.4× 35 0.7× 46 271
Panagiota Matsouka Greece 10 97 0.5× 70 0.4× 119 1.0× 58 0.5× 37 0.8× 23 369
Marco Fossati Italy 9 69 0.3× 86 0.5× 46 0.4× 92 0.8× 29 0.6× 22 264
Dawn Swan Ireland 11 186 0.9× 85 0.5× 79 0.7× 61 0.5× 49 1.0× 43 377
Julie Milojevic Switzerland 6 67 0.3× 36 0.2× 27 0.2× 157 1.4× 50 1.0× 9 359
Güner Hayri Özsan Türkiye 9 92 0.5× 84 0.5× 26 0.2× 26 0.2× 17 0.4× 34 229

Countries citing papers authored by M. A. Hussein

Since Specialization
Citations

This map shows the geographic impact of M. A. Hussein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. A. Hussein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. A. Hussein more than expected).

Fields of papers citing papers by M. A. Hussein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. A. Hussein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. A. Hussein. The network helps show where M. A. Hussein may publish in the future.

Co-authorship network of co-authors of M. A. Hussein

This figure shows the co-authorship network connecting the top 25 collaborators of M. A. Hussein. A scholar is included among the top collaborators of M. A. Hussein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. A. Hussein. M. A. Hussein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dimopoulos, Meletios Α., et al.. (2014). Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer Journal. 4(11). e257–e257. 34 indexed citations
2.
Dimopoulos, Meletios Α., M. A. Hussein, Arlene S. Swern, & Daniela Weber. (2011). Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia. 25(10). 1620–1626. 18 indexed citations
3.
Hussein, M. A., James R. Berenson, Rubén Niesvizky, et al.. (2010). A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 95(5). 845–848. 112 indexed citations
4.
Mourad, W.F., Ayman Saad, Jimmy J. Caudell, et al.. (2010). Postradiation therapy sarcoma.. Journal of Clinical Oncology. 28(15_suppl). e20523–e20523. 4 indexed citations
5.
Hussein, M. A., Frank D. Vrionis, Robert D. Allison, et al.. (2008). The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia. 22(8). 1479–1484. 46 indexed citations
6.
Berenson, James R., Donna Reece, Ralph V. Boccia, et al.. (2007). ZIO-101 (S-dimethylarsino-glutathione): Phase I/II trials in advanced/progressive multiple myeloma. Journal of Clinical Oncology. 25(18_suppl). 8109–8109. 6 indexed citations
7.
Baz, Rachid, Esteban Walker, Toni K. Choueiri, et al.. (2006). Recombinant Human Erythropoietin Is Associated with Increased Overall Survival in Patients with Multiple Myeloma. Acta Haematologica. 117(3). 162–167. 19 indexed citations
8.
Baz, Rachid, Megan Kelly, Janice Reed, et al.. (2006). Phase II study of dexamethasone, ascorbic acid, thalidomide and arsenic trioxide (DATA) in high risk previously untreated (PU) and relapsed/refractory (RR) multiple myeloma (MM). Journal of Clinical Oncology. 24(18_suppl). 17535–17535. 3 indexed citations
9.
Hussein, M. A., Holly Gundacker, David R. Head, et al.. (2005). Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706. Leukemia. 19(11). 1880–1886. 2 indexed citations
10.
Baz, Rachid, et al.. (2005). High dose recombinant human erythropoietin use is associated with increased overall survival in patients with multiple myeloma. Journal of Clinical Oncology. 23(16_suppl). 6621–6621. 5 indexed citations
11.
12.
Hussein, M. A., et al.. (2004). Updated results from a randomized multicenter trial of DVd vs VAd in patients with newly diagnosed multiple myeloma. Journal of Clinical Oncology. 22(14_suppl). 6509–6509. 5 indexed citations
13.
Hussein, M. A., Mark Wildgust, John Fastenau, & Catherine Tak Piech. (2004). Cost effectiveness of DVd vs VAd in newly diagnosed multiple myeloma. Journal of Clinical Oncology. 22(14_suppl). 6548–6548. 2 indexed citations
14.
Ramasubbu, Kumudha, Tarun Mullick, Anna P. Koo, et al.. (2003). Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case‐based review. Transplant Infectious Disease. 5(2). 98–103. 40 indexed citations
15.
Hussein, M. A., et al.. (2003). Skeletal Trauma Preceding the Development of Plasma Cell Dyscrasia: Eight Case Reports and Review of the Literature. Medical Oncology. 20(4). 349–354. 8 indexed citations
16.
Hussein, M. A., et al.. (2003). Etanercept Therapy in Patients with Advanced Primary Amyloidosis. Medical Oncology. 20(3). 283–290. 15 indexed citations
17.
El‐Nawawy, Ahmed, et al.. (2002). Evaluation of erythropoiesis in protein energy malnutrition. Eastern Mediterranean Health Journal. 8(2-3). 281–289. 18 indexed citations
18.
Hussein, M. A., et al.. (1994). Multiple myeloma: an overview of diagnosis and management. Cleveland Clinic Journal of Medicine. 61(4). 285–298. 13 indexed citations
19.
Hussein, M. A.. (1991). Analysis and Forecasting Infant Mortality Rate (IMR) In Egypt Until Year 2000. PubMed. 25(2). 32–46. 1 indexed citations
20.
Hussein, M. A., et al.. (1990). Platelet transfusions administered to patients with splenomegaly. Transfusion. 30(6). 508–510. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anup J. Devasia Breakdown of academic impact, for papers by A. Zuiable Breakdown of academic impact, for papers by Arif Alam Breakdown of academic impact, for papers by Waleed Sabry Breakdown of academic impact, for papers by Ozan Salim Breakdown of academic impact, for papers by Panagiota Matsouka Breakdown of academic impact, for papers by Marco Fossati Breakdown of academic impact, for papers by Dawn Swan Breakdown of academic impact, for papers by Julie Milojevic Breakdown of academic impact, for papers by Güner Hayri Özsan
Rankless by CCL
2026